MOTS-c: natural mitochondrial peptide tied to metabolism and longevity
A small signaling peptide the body makes from its own mitochondrial DNA; it boosts cellular energy use, rises with exercise, and declines with age, experimental, not yet an approved drug.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
FDA-tracked compound — synthesized for clinical/research use
Fork this card to add platform evidence →
FDA-tracked (reclassified Category 1, Feb 2026) — preclinical/clinical bioassay data exists
Fork this card to add platform evidence →
What this is
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino-acid peptide that the body produces from its own mitochondrial DNA — making it one of a rare class of signals that originates in the cell's energy machinery rather than in the nucleus. It was discovered in 2015 by Pinchas Cohen and Changhan Lee at the USC Leonard Davis School of Gerontology and published in Cell Metabolism (Lee and colleagues 2015). Endogenous MOTS-c levels increase with acute exercise in humans and decline with aging. A mitochondrial DNA polymorphism in the MOTS-c coding region has been associated with type 2 diabetes risk in certain populations, suggesting MOTS-c plays a role in normal human metabolic regulation.
History
MOTS-c was first described in 2015 by Lee and colleagues at the University of Southern California (Cell Metabolism 2015). The conceptual novelty was stark: the peptide is encoded within a small open reading frame embedded inside the mitochondrial 12S ribosomal RNA gene — one of only a handful of peptides whose gene sits within mitochondrial rather than nuclear DNA. Humanin, also characterized by the Cohen lab, was the prototype mitochondria-derived peptide; MOTS-c extended the concept to a metabolically active regulator with exercise-responsive circulating levels. The initial paper showed MOTS-c levels rise after acute exercise in humans and that exogenous administration improved insulin sensitivity and reduced obesity in high-fat-diet mice. Subsequent work extended the biology into muscle, cardiovascular, bone, and aging contexts. A pro-diabetogenic mitochondrial DNA polymorphism in the MOTS-c coding region was later identified (Reynolds and colleagues 2021, Nature Communications). Despite scientific traction, MOTS-c has not entered late-stage clinical development; what is sold under the MOTS-c label is synthetic peptide produced outside the regulated pharmaceutical supply chain, with no FDA-approved therapeutic indication.
What it does
MOTS-c activates AMPK — the cell's core energy-sensing switch — through a cascade that begins in the mitochondria. AMPK activation promotes glucose uptake, fatty acid oxidation, and mitochondrial biogenesis; it is the same pathway engaged by exercise and metformin. In addition to this cytoplasmic role, MOTS-c translocates to the nucleus under metabolic or oxidative stress, where it directly adjusts gene expression linked to antioxidant defense and metabolic adaptation — an unusual retrograde signaling route from organelle to nucleus. In skeletal muscle models, it promotes GLUT4 translocation to the cell surface, improving insulin-stimulated glucose clearance. Animal studies show exogenous MOTS-c reduces fat mass, improves glucose tolerance, and slows age-related physical decline; endogenous circulating MOTS-c levels in humans correlate inversely with insulin resistance, obesity, and cardiovascular risk markers.
Evidence
- Human: Observational only. Multiple cross-sectional studies link lower circulating MOTS-c to insulin resistance, obesity, and PCOS (Kim and colleagues 2018, Cell Reports; plasma MOTS-c studies 2018). A multicenter cohort study identified endogenous MOTS-c as a mortality predictor in hemodialysis patients. Human exercise studies consistently show acute endurance exercise raises circulating MOTS-c. No controlled interventional trial of exogenous MOTS-c has been completed; a first-in-human trial in insulin resistance was registered in 2025 with no results available at time of writing. CohBar's CB4211 — a MOTS-c analog with modified pharmacokinetics, not MOTS-c itself — completed a Phase 1b study in 20 obese NAFLD patients (25 mg SC daily, 4 weeks) showing reductions in ALT, AST, and glucose versus placebo; Phase 2 never ran after CohBar wound down in 2023. This supports MOTS-c-derived pharmacology in humans but does not constitute evidence for MOTS-c itself.
- Animal: Extensive. Diet-induced obesity and aging models show AMPK activation, improved insulin sensitivity, reduced fat mass, and prevention of muscle atrophy. Reynolds and colleagues (Nature Communications 2021) demonstrated enhanced physical performance in young, middle-age, and old mice. Cardiac protection and myocardial performance improvement in exercise-trained rats have been reported. Multiple independent research groups have replicated core metabolic findings.
- In vitro: AMPK activation via AICAR accumulation demonstrated; MOTS-c translocates to the nucleus under oxidative and metabolic stress (MOTS-c nuclear translocation study 2018, Cell Metabolism); GLUT4 upregulation in skeletal muscle cell models; folate-methionine cycle inhibition as the upstream trigger of AICAR accumulation.
Known effects
- Insulin sensitization / glucose tolerance — Preclinical (animal); supported by original 2015 Cell Metabolism paper and multiple independent replications; human observational correlation only
- Exercise-responsive circulating levels — Human; established biomarker finding across multiple RCT and observational studies
- Improved physical performance in aging — Animal (Reynolds and colleagues 2021, Nature Communications); young, middle-age, and old mice; no human interventional data
- Muscle atrophy reduction — Animal; myostatin and atrophy signaling reduced in preclinical models
- Cardiac/myocardial effects — Animal; preclinical models of heart failure and exercise training
- Mortality correlation in dialysis patients — Human observational; multicenter cohort study; endogenous levels only
- Endocrine marker changes with cancer radiation — Human observational; serum MOTS-c levels measured in patients with lung and breast cancer receiving radiation therapy
Safety signals
No clinical safety trial for MOTS-c itself has been completed. All available human safety data come from the CB4211 analog program: Phase 1a in 65 healthy volunteers identified persistent injection-site reactions as the primary adverse event; no serious adverse events were reported. For MOTS-c itself, safety in humans is entirely uncharacterized.
Theoretical concern — additive effects with glucose-lowering agents: MOTS-c activates AMPK and improves insulin-stimulated glucose uptake; source literature describes potential additive hypoglycemia risk with insulin, sulfonylureas, meglitinides, and metformin. No controlled interaction data in humans exists.
Research-chemical quality: source literature notes synthetic MOTS-c sold through research-chemical channels varies in purity, peptide identity, and endotoxin contamination; 16-residue synthesis complexity increases contamination risk relative to shorter peptides. Chronic exogenous AMPK activation has not been studied at any dose or duration in humans.
Regulatory status
- US (FDA): Not approved. Removed from the 503A Category 2 compounding nomination list (April 2026; nomination withdrawn). FDA intended to consult PCAC in July 2026 regarding MOTS-c acetate and free-base forms — outcome not yet reflected in this card. No compounding authorization; no prescription pathway. Sales occur through research-chemical suppliers.
- EU (EMA): No marketing authorization.
- UK (MHRA): No license.
- Canada: No approval; investigational only.
- Australia (TGA): No approval; general enforcement action against unapproved peptide sales applies.
- WADA: Prohibited under S0 (non-approved substances for human therapeutic use) per available sources; current list status not independently refreshed for this card.
Mechanism
MOTS-c (sequence MRWQEMGYIFYPRKLR; 16 residues; endogenously encoded in the mitochondrial 12S rRNA gene) activates AMPK through inhibition of the folate-methionine cycle, leading to accumulation of AICAR — an endogenous AMPK activator first shown in the original 2015 Cell Metabolism paper. AMPK activation drives glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. MOTS-c also translocates to the nucleus under metabolic or oxidative stress to regulate gene expression related to antioxidant response and metabolic adaptation — a mechanism characterized in cell and animal models (Kim and colleagues 2018, Cell Metabolism). GLUT4 translocation to the plasma membrane in skeletal muscle improves insulin-stimulated glucose clearance. In rodent exercise models, MOTS-c interacts synergistically with physical activity to regulate PGC-1α expression and attenuate insulin resistance via AMPK signaling (Zhu and colleagues 2021, Biochimica et Biophysica Acta). The nuclear translocation mechanism depends on intracellular MOTS-c; whether subcutaneously injected synthetic MOTS-c reaches the relevant intracellular compartments to reproduce this pathway is unresolved.
Open questions
- Human pharmacokinetics — absorption, distribution, half-life, and tissue uptake of exogenous MOTS-c have not been characterized in humans at any dose or route
- Nuclear translocation recapitulation — the mitochondria-to-nucleus translocation that drives much of the interesting biology may not be recapitulated by subcutaneous dosing; whether injected synthetic MOTS-c reaches the intracellular compartments relevant to its mechanism is unresolved
- Translation of observational signals — human studies link endogenous MOTS-c levels to metabolic health, but whether raising levels via exogenous dosing reproduces the protective associations is untested
- CB4211 vs MOTS-c equivalence — CB4211 has modified pharmacokinetics; its Phase 1b signal may or may not generalize to the parent molecule
- Long-term safety — chronic exogenous AMPK activation has not been studied in humans at any dose or duration
- Dose-ranging — no controlled trial has identified minimum effective or maximum tolerated human doses
Myths and misconceptions
- "MOTS-c can replace exercise." Exercise activates hundreds of adaptive pathways across cardiovascular, musculoskeletal, neural, and metabolic systems. MOTS-c engages a subset of metabolic signaling that overlaps with exercise — primarily AMPK — but does not reproduce the full physiological response (Lee and colleagues 2015).
- "Because MOTS-c is naturally produced in the body, exogenous MOTS-c is automatically safe." Endogenous MOTS-c is regulated by mitochondrial gene expression and metabolic state. Subcutaneously injected synthetic MOTS-c bypasses that regulation entirely, and its safety profile in humans has not been characterized at any dose.
- "MOTS-c is FDA-approved or in late-stage clinical development." MOTS-c is not FDA-approved for any indication and has not entered late-stage human trials. The published human evidence is largely observational — measuring endogenous MOTS-c levels in patient populations — not interventional.
Related peptides
- Humanin — the prototype mitochondria-derived peptide (MDP) from the same research lineage; acts through different receptors with neuroprotective emphasis (card not yet linked)
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Could a mitochondrial peptide keep muscles strong during long-term steroid treatment?
If true, patients on prednisone or similar drugs for arthritis, asthma, or autoimmune disease could keep their muscle strength. That would mean fewer falls, better mobility, and less disability during treatment.
Could attaching a fat molecule to MOTS-c make it last long enough for weekly shots?
If true, patients with diabetes or age-related metabolic decline could take a simple weekly injection instead of daily pills. That would mean better adherence, lower cost, and a more practical path from lab to pharmacy.
Could a tiny peptide boost energy balance just by touching the cell surface?
If true, we could redesign MOTS-c to target specific organs by changing its surface charge. That would mean safer, more precise metabolic drugs for people with diabetes or age-related weight gain.
Could the first two building blocks of MOTS-c act like a tiny anchor on cell membranes?
If true, drug designers could swap those first two blocks to make MOTS-c last longer or hit different tissues. People with insulin resistance could get more effective, longer-lasting treatments.
Could a tiny genetic typo in MOTS-c rob some people of their natural metabolic protection?
If true, doctors could test for this variant and give MOTS-c replacement to those who need it most. That would mean earlier, personalized prevention of type 2 diabetes in high-risk families.
Could a tiny metabolic peptide help people stay strong enough to finish cancer immunotherapy?
If true, more patients could complete their full course of immunotherapy and respond better. That would mean longer survival and fewer treatment stops due to weakness or weight loss.
▸full evidence table1 metrics
| metric | value | tool |
|---|---|---|
| ranking score | 0.5723018646240234 | boltz-2 |
▸3-letter notation
▸recipeboltz-2 2.2.1
| parameter | value |
|---|---|
| model | boltz-2 2.2.1 |
| weights | — |
| hardware | vast_v100_32gb |
| mlx version | — |
| python | — |
| random seed | 1 |
| msa strategy | none_monomer |
| runtime | — |
| predicted by | — |
| predicted at | 2026-05-23 |
▸citationbibtex
@peptide{pep00003,
sequence = {MRWQEMGYIFYPRKLR},
target = {longevity},
author = {peptidemodel},
year = {2026},
status = {bioassayed}
}